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ABSTRACT 
 
Lung cancer is currently the most deadly form of cancer due to the fact that metastasis occurs 
in the lymph nodes making it difficult to remove by surgical means. Chemotherapy has been 
the most successful method of treatment, although it has been harmful to human health as a 
consequence of non-specific cytotoxicity. There has been, therefore, a growing interest in 
cancer research to develop alternative cancer treatments, which are less toxic. Currently 
plant-derived drugs are perceived to be more effective as they display both cytotoxic activity 
and are less harmful to overall human health. Thus the aim of the study was to determine the 
cytotoxic effects of the plant Lobostemon fruticosus on A549 cells. The IC50 of the methanol 
and butanol extracts of L. fruticosus were obtained at 40 µg/ml and 50 µg/ml, respectively. 
DNA fragmentation was observed after 48 hour exposure to treatments, indicating that the 
plant extracts induced apoptosis. Cell cycle analysis indicated that the plant extracts inhibited 
cell cycle progression at the sub-G0 phase, which indicated that the cells had undergone 
apoptosis. RT-PCR showed that the expression of p53 was down-regulated; however, p21 
and Bax were up-regulated in all treatments. LC-MS identified that the compounds from the 
plant extracts are known apoptotic inducers. The results lead to the conclusion that the 
extracts of L. fruticosus, induce cell death in A549 cells. The plant extracts induced a p53-
independent apoptotic mechanism, which was mediated by Bax and p21.                        
Key words: Lobostemon fruticosus, camptothecin, taxol, Non-small cell lung cancer 
(NSCLC) 
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Chapter One: Introduction and Literature Review 
1.1. Medicinal plants and their use in traditional medicine  
Medicinal plants have been used throughout human history. The chemical compounds 
produced in plants, known as secondary metabolites, have been known to play an important 
role in their biological functions. Plants use secondary metabolites as a defence mechanism 
against predation from insects and herbivores. Furthermore, these compounds are known to 
be an effective defence against fungal infections (Desai et al., 2008). These properties have 
been manipulated for centuries through various methods of extraction and used as medicine 
for many communities around the world (Rahmatullah and Biswas, 2012) . The use of plants 
as traditional medicine remains a prevalent practice to date in many rural communities devoid 
of access to modern medicine (Fabricant and Farnsworth, 2001). These communities continue 
to thrive due to the extensive knowledge of medicinal properties of the various medicinal 
plants used by traditional healers, many of which are still being discovered by modern 
medicine.  In various countries, plants from numerous families have been used to treat 
various ailments that affect the community (Amira et al., 2012). For example, Phylolocca 
dodencandra was used to treat and control the prevalence of schistosomiasis as the plant was 
commonly known to be an effective molluscicide (Lemma, 1971). There has been a notable 
increase in the use of medicinal plants for commercial purposes these past three decades (Cai 
et al., 2004; Amira et al., 2012). In agricultural practices, medicinal plants have been used for 
several centuries for maintenance and conservation of livestock health, such as the use of 
Polokowskia tabacco to treat intestinal disorder in cows (Amira et al., 2012). 
Phytochemicals, such as phenolics, are organic compounds that are naturally found in plants 
and are non-nutritive bioactive substances that have been linked with the anti-cancer 
properties in a variety of plant based foods (Tapsell et al., 2006). Furthermore, these 
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compounds have various anti-inflammatory and anti-oxidant properties that aid in reducing 
the damage caused by free and active oxygen within the system (Amira et al., 2012). This is 
mainly due to the fact that plants contain various compounds including flavonoids and phenyl 
propanoids, which are effective anti-oxidants (Cai et al., 2004). 
1.1.1. Lobostemon fruticosus  
Lobostemon fruticosus is a plant that is indigenous to South Africa and commonly referred to 
as pyjama bush (English), agdaegeneesbos and douwurmbos (Afrikaans) (Levyns, 1934). It is 
a member of the Boraginaceae family otherwise referred to as the ‘forget-me-nots’ (Hilger 
and Böhle, 2000). The shrub which can reach heights of 1 m and is characterised with 
densely hairy branches, oval-shaped leaves and long (25 mm) funnel-shaped flowers that 
often appear in a variety of colours, ranging from purple to white, which is a known 
characteristic of plants found in the Boraginacaeae family (Levyns, 1934; Hilger and Böhle, 
2000). Lobostemon Fruticosus is widely distributed along Namaqualand, the Cape Peninsula 
and Worcester, and was used as a popular old Cape remedy shrub by the Khoisan, the settlers 
and Malays (Levyns 1934). The leaves were used as a tea to cure ringworms, the lotion was 
applied to wounds and a lotion was made from a mixture with Meliathus comosus and 
Galenia africana was used to cure syphilis (www.plantsafrica.com). The plant was believed 
to cure any ailment within eight days, hence the name agtedaegeneebos. However, little is 
known about the chemistry of this plant. Well known members of the family contain 
napthoquinone derivatives, pyrrolizidine alkaloids, cyclitols, phenolic acids, tannins and 
ureide allatonins (found in the comfrey root) (www.plantsafrica.com). Some of the extracts 
that were mentioned above, such as napthoquinone derivatives and saponins, are known to 
have cytotoxic effects in cancer cells (Huang and Zou, 2011; Cui et al., 2011).  
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1.2. Cancer 
1.2.1. Cancer 
Cancer is a genetic disease that results in uncontrolled cell division. It is brought about by 
mutations in genes that cause an increase in the rate of cell proliferation and a decrease in 
apoptosis (Erenpreisa and Cragg, 2007). Throughout the ages researchers have been able to 
identify environmental, chemical and physiological factors (or carcinogens) that lead to 
cancer formation within the human body (Meng et al., 2012; Wogan et al., 2004). These 
carcinogens were directly linked to an increase in tumour incidences in animals and humans 
(Ames, 1983; Ames and Gold, 1990) . The process with which cancer is formed as a result of 
carcinogens (called carcinogenesis), results from either genetic mutation or epigenetic 
changes. The cancer cells gain a selective advantage and undergo clonal expansions as a 
result of pro-oncogenes.(Ames and Gold, 1990; Henderson and Feigelson, 2000). 
Many physiological processes, such as metabolism may produce highly reactive oxygen 
species (ROS) and other endogenous carcinogens, which can lead to oxidative destruction of 
biomolecules (catabolism) (Yager, 2000). A large production of these ROS by-products could 
result in the development of degenerative diseases such as atherosclerosis, cancer and 
diabetes in humans (Halliwell and Cross, 1994; Cai et al., 2004) . The secondary metabolites 
such as phenolic compounds, tannins, quinines and vitamins found in plants have antioxidant 
properties and they reduce the high incidence of free radicals and ROS within the body (Cai 
et al., 2004; Campbell et al., 2005). There have not been a lot of studies done to investigate 
the effects of Lobostemon fruticosus on cancer cells; therefore, it would be interesting to 
investigate whether this medicinal plant has any cytotoxic effects on lung cancer cells. 
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1.2.2. Lung cancer 
Lung cancer is among the most frequently reported cases of cancer worldwide, with a 13-
15% occurrence of all known cancers being reported daily (WHO, 2009). Lung cancer is also 
the most deadly form of cancer as it has been observed to be resistant to most therapeutic 
treatments and it demonstrates metastasis within lymph nodes (Burris, 2009; Benlloch et al., 
2009). Over the past two decades there has been an increase in the number of lung cancer 
incidences and its mortality rate has also increased (Weill et al., 2000). 
In South Africa, lung cancer is the second leading cancer in males and the 6
th
 leading form of 
cancer in women (Groenewald et al., 2007). Sixty percent of the leading causes of cancer are 
related to smoking, this form of cancer affects secondary smokers or passive smokers as well 
as primary smokers (Sitas et al., 2004; Groenewald et al., 2007). Other known causes are 
industrial and domestic air pollution. Most lung cancers start of on the cells lining the interior 
passage of the lung and are referred to as bronchogenic carcinomas (Kellermann et al., 1973; 
Engels, 2008). HIV/AIDS has also been listed as a causative agent for lung cancer together 
with various other forms of cancer (Engels, 2008). 
Lung cancer incidences were once recorded to be low in developing countries as compared to 
developed countries like the United States of America and United Kingdom (Alberg and 
Samet, 2003). This was mainly due to the higher rates of cigarette smoking and due to 
industrial wastes omitted near the cities in developed countries. However, with a change in 
people’s life styles, in developing countries, and the more industries being built to boost the 
economy of developing countries, the incidence of lung cancer has increased drastically. 
Nearly 90% of most non-small cell lung cancer (NSCLC) occurrences are believed to be 
caused by cigarette smoking and about 10% is a result of industrial toxic products such as 
asbestos and radon gases (Engels, 2008). These cases were investigated as the use of tobacco 
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has always been prevalent in developing countries and there was still a very low incidence of 
lung cancer cases in developing countries (Mzileni et al., 1999). However, research has 
shown that the introduction of various chemicals in cigarettes, meant to make them more 
addictive, have contributed to the development of lung cancer in regular smokers (Winkler et 
al., 2013). 
Changes in modern lifestyle over the years have permitted youth to start smoking at earlier 
stages of their lives and some children are being subjected to secondary smoke inhalation as 
young as two years (Lam et al., 2004). Moreover, there has been an increase in the number of 
women who smoke as a result of these lifestyle changes.   These factors have also contributed 
to the increase in lung cancer incidences in developing countries such as those in African and 
Asia (Lam et al., 2004).  
There has been a very low survival rate in patients with lung cancer; the low prognosis is due 
to the fact that patients are rapidly diagnosed with lung cancer in the late stages when the 
symptoms begin to present themselves. This is due to the limited forms of lung cancer 
screening tests (Parkin and Moss, 2000). Furthermore, patients diagnosed with lung cancer at 
the late stage rarely live longer than five years after diagnosis (Benlloch et al., 2009). 
Therefore, there have been various attempts to try and cure late stage lung cancer (Kelly et 
al., 2001).  
Currently, there are three known approaches to lung cancer treatment, namely, surgical 
resection, radiotherapy and chemotherapy (Ettinger et al., 2010). Surgery offers the best 
chance of curing NSCLC in patients with advanced lung cancer. However, only a limited 
amount of patients are suitable for surgical resection and therefore a large amount of affected 
patients opt for non-surgical approaches (Ettinger et al., 2010). Radiotherapy is a non-
surgical approach  that has been used as an alternative to surgical resection, however, there 
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has only been a report of only 10% of lung cancer patients who have been cured after 
radiotherapy (Jassem, 2007; Klastersky and Awada, 2012). As a result some patients also 
have used chemotherapy as the next non-surgical alternative, however, this option has been 
the cause of an overall deterioration in patient health (Ettinger et al., 2010). 
Chemotherapeutic drugs are non-specific and seem to affect both healthy and cancerous cells 
within the patient. Furthermore, there have been reports of an increased resistance to current 
therapies on patients with advanced lung cancer cells (Sechler et al., 2013). Therefore, there 
is currently an urgent need to develop a better alternative in lung cancer treatments. 
A tumour that is localised within a specific area, a lump, can be treated with high energy 
radiation which can damage the DNA of the cancerous cells (Shipley et al., 1999). This is 
due to the fact that DNA from cancerous cells lacks the ability to repair damages as opposed 
to that in normal cells (Mathews et al., 2000; Kerr et al., 1994). However, metastatic or 
malignant tumours are treated with chemotherapeutic drugs, which are toxic to actively 
dividing cells. These drugs are administered to the circulatory system and interfere with the 
cell cycle (Arap et al., 1998). These drugs do, however, interfere indiscriminately with 
normal cells as well as cancerous cells and may result in various unpleasant side effects 
(Arap et al., 1998).   
The body also has a way of dealing with unwanted proliferation. Once DNA has been 
damaged three possible outcomes may occur; the damaged DNA could be efficiently repaired 
leading to normal cellular function, DNA could be irreparably damaged leading to a mutation 
or systematic cell death (apoptosis) (Kerr et al., 1994). It has been discovered that the genes 
that are affected during the formation of cancer play a significant role in cellular 
development, immune response and various other biological processes (Huang et al., 1988). 
Cancer causing genes, or oncogenes, arises from genetic changes from normal pro-oncogenes 
that are involved in cell growth and division. This change arises as a result of various genetic 
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errors in the proto-oncogenes, namely translocation, amplification and point mutations 
(Zhang et al., 2010). These errors result in changes in the gene product which lead to the 
production of protein that is defective and resistant to degradation and thus result in 
abnormalities within the cell cycle and result in cancer formation (Campbell et al., 2005). 
Furthermore, these mutations can affect tumour suppressor genes, which produce proteins 
that prevent uncontrolled cell growth (Greenblatt et al., 1994; Sager, 1989). These tumour 
suppressor proteins repair damaged DNA, control anchorage to cell matrix and are 
components of the cell signalling pathway which regulate the cell cycle in normal cells 
(Sager, 1989). An example of this could be the production of p53 protein which is actively 
involved in the repair of damaged DNA. If the damaged DNA is irreparable the p53 protein 
activates pro-apoptotic genes. The product proteins of the pro-apoptotic genes induce 
apoptotic cell death(Campbell et al., 2005).  
1.3. Cell cycle 
Cell division occurs sequentially within a eukaryotic system. There are stop and go signals 
that trigger the period of cell division and its senescence (Erenpreisa and Cragg, 2007). The 
cell cycle can be distinguished by the interphase and the mitotic phase (Campbell et al., 
2005). The interphase, referred to as the longer phase of the cell cycle, accounts for nearly 
90% of the entire cycle. It is divided into various sub phases, namely, the G0 phase (stage at 
which cell growth is stunted), G1 phase (first gap phase) also referred to as the restriction 
point with which cell growth is either allowed or entered into the G0 phase (Hartwell and 
Weinert, 1989; Campbell et al., 2005). The S phase is the stage at which DNA synthesis 
occurs and finally the G2 phase (second gap phase) that precedes the mitotic phase of the cell 
cycle. 
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Figure 1. A schematic diagram of the cell cycle, displaying the various phases of the cycle 
namely the G0, G1, G2, S and M phases. 
 
1.3.1. Loss of cell cycle control in cancer cells 
Cancer cells do not respond systematically to the body’s regular control system because of 
their uncontrollable proliferation and concurrent invasion of other tissue (Sherr, 1996). This 
may be due to their apparent independence to the presence of growth factors or rather due to 
an abnormality that may occur  in the signal pathways responsible for conveying growth 
factor signals to the cell cycle control system (Campbell et al., 2005). Furthermore, this 
uncontrollable proliferation could be as a result of an abnormal cell cycle control system 
(Hartwell and Kastan, 1994). Various studies have shown that abnormal cells could stop 
proliferating at random check points. However, there has been little evidence of this 
occurrence in cancer cells (Kastan et al., 1995). Tumour cells are found to have an unusual 
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number of chromosomes and secrete signal molecules that cause rapid and unhindered cell 
growth (Lengauer et al., 1998).    
1.4. Apoptosis  
Apoptosis, also known as programmed cell death, is the most vastly investigated topic in 
modern cell biology (Wong, 2011). Not to be confused with necrosis, in which cell death is 
brought about as a result of strenuous conditions affecting the cells surroundings. Apoptosis 
occurs as a result of the cell actively participating in the process of cell death due to specific 
stimuli in the cell’s environment (Nanji and Hiller-Sturmhofel, 1997; Kroemer, 1999). The 
process of apoptosis is fundamental in natural cell death of the cell with damaged DNA after 
radiation exposure, and in pathological processes brought about anticancer drugs (Wong, 
2011). The changes in cellular morphology, induced by apoptosis, appears similarly in almost 
all the eukaryotic cells as it affects both the nucleus and the cytoplasm of the cell (Hacker, 
2000). However, the time it takes to complete the process of cell death varies from cell to cell 
based on the stimuli and the pathways that lead to apoptosis (Hacker, 2000). 
To understand the conditions that affect apoptosis in cancerous cells, one must have a 
knowledge of the mechanism of apoptosis (Hacker, 2000). This understanding is  essential 
when designing drugs that target specific apoptotic pathways and the genes involved (Wong, 
2011). The molecules that play a central role in this process are caspases, also known as 
cystein-aspartic proteases, which when activated cleave various proteins that either become 
activated or deactivated  in order to carry out a cascade of reactions that will eventually result 
in apoptosis (Favaloro et al., 2012; Wong, 2011). Researchers have identified three main 
pathways that are involved in apoptosis, namely the intrinsic and extrinsic pathways which 
are well known and eventually lead to a common pathway (see Figure 1) (Favaloro et al., 
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2012). The third pathway occurs in the endoplasmic reticulum, although very little is known 
about this current pathway (Wong, 2011) and thus it will not be discussed further.  
1.4.1. The intrinsic pathway 
The intrinsic pathway, also referred to as the mitochondrial pathway, is initiated within the 
cell and the initial processes in this pathway utilise mitochondrial proteins (Favaloro et al., 
2012). These proteins leak out of the mitochondrial membrane to promote apoptosis, as a 
result of the specific signals that were elicited. Cytochrome c, a protein involved in electron 
transfer inside healthy mitochondrial organelles, acts as a death factor outside the 
mitochondria. This process is triggered by internal conditions within the cell, such as DNA 
damage, hypoxia and severe oxidative stress (Wong, 2011). The BCL-2 family are important 
in  regulating the intrinsic pathway (Gross et al., 1999). The members of this protein family 
are divided into the pro-apoptotic and anti-apoptotic groups. Proteins such as Bcl-2, Bcl-X 
and Bcl-W are characterised as anti-apoptotic; whereas Bax, Bak and Bad proteins are pro-
apoptotic (Korsmeyer, 1999). The proteins that are anti-apoptotic inhibit the secretion of 
cytochrome-c  from mitochondria, and those that are pro-apoptotic trigger the release of 
cytochrome-c (Gross et al., 1999). Mitochondrial outer membrane permeabilisation 
(MOMP), otherwise known as mitochondrial leakage, occurs as a result of stress brought 
about by pro-apoptotic proteins that directly affect the mitochondrial membrane (Wong, 
2011). These proteins bind to the mitochondrial membrane causing the formation of pores 
(Korsmeyer, 1999). Upon release cytocrome-c binds to an apoptotic protease activating factor 
(APAF-1) and inactive caspase 9 (Procaspase 9), to form a large apoptosome complex. 
Caspase 9 is then activated upon autocatalysis. In addition, either the Smac/DIABLO or the 
Omi/HtrA2 promoters will bind to inhibitor of apoptosis proteins (IAP) (Favaloro et al., 
2012). AIP’s inhibit the activation of caspases in non-apoptotic conditions. However, the 
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binding of these specific promoters can often disrupt the interaction between AIP and 
caspases. This leads to caspases activation, which initiates apoptosis (Korsmeyer, 1999). 
1.4.2. Extrinsic Pathway 
The extrinsic pathway, often referred to as the death receptor pathway, is activated by death 
receptors upon ligand binding. Most death receptors are from the TNF/NGF family (Kerr et 
al., 1994). Popular death TNFR1 and Fas (CD95) interact with specific extracellular ligands 
called TNF and Fas ligand respectively (Wong, 2011). Upon ligand binding these trans-
membranal receptors recruit adapter proteins called TNF receptor-associated death domain 
(TRADD), Fas-associated death domain (FADD) specific for either one of the receptors, 
together with inactive caspase 8 (Procaspase 8) (Favaloro et al., 2012) The newly formed 
ligand-receptor-adapter protein complex (now referred to as the death-induced signal 
complex (DISC)), activates caspases 8, which initiates apoptosis (Favaloro et al., 2012; Fulda 
and Debatin, 2004). 
As mention earlier, both the intrinsic and extrinsic pathway reach convergent apoptotic 
pathway. Caspase 9 is the upstream caspases for the intrinsic pathway whereas caspase 8 is 
for the extrinsic pathway. Both these caspase are therefore referred to as the initiator caspase 
in their respective pathways (Fulda and Debatin, 2004). These  two pathways converge at 
caspase 3 activation, a process facilitated by the activation of both caspase 9 and 8 for the 
intrinsic and extrinsic pathways respectively (Favaloro et al., 2012). Once active caspases 3, 
which is the most common executioner caspase, activates the caspase-activated 
deoxyribonuclease, an enzyme responsible for the disruption of nuclear apoptosis (Baud and 
Karin, 2001; Fulda and Debatin, 2004). Furthermore caspase 3 cleaves and subsequently 
activates other caspases which are responsible for the several cellular proteins, namely, DNA 
repair protein kinases, and several other proteins that are involved in cellular integrity 
(Favaloro et al., 2012). These protein degradations affect the cell cycle, signalling pathways 
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and the cellular cytoskeleton, resulting morphological changes in cellular structure, indicative 
of apoptosis (Fulda and Debatin, 2004). 
1.4.3. Apoptotic genes and proteins 
a)  P53 tumour-suppressor gene and its protein product 
The p53 (TP53) gene is the most common tumour-suppressor gene. TP53 has a molecular 
weight of 53 kDa, which is indicative of its name (Campbell et al., 2005). TP53 plays a 
crucial role in the inhibition of cell proliferation, it functions as a transcriptional factor that 
promotes the synthesis of cell cycle-inhibiting proteins (Thor et al., 1992). TP53 has variety 
of cellular functions which include, DNA repair, thus preventing the formation of cancer 
causing mutations, and playing a role in cell signalling pathways that inhibit the cell cycle 
(Ryan et al., 2001). The protein is activated by various physiological stressors, such as DNA 
damage; upon activation, p53 activates other genes such as the p21 gene (Komarova et al., 
2000). P21 binds to cyclin-dependent kinases (cdk’s), thereby halting the cell cycle and 
allowing the DNA repair process (Komarova et al., 2000). However, in the case where DNA 
is irreparable, TP53 will activate pro-apoptotic genes, such as Bax, that  induce apoptosis 
(Campbell et al., 2005).  
Among all the human cancer cases recorded more than 50% were found to be as a result of a 
defective p53 gene (Wong, 2011). Studies have shown that mutations in this particular gene 
were common in cancer (Sigal and Rotter, 2000). These findings showed the crucial role p53 
plays in regulating the cell cycle and apoptosis. Cyclin dependent kinases play a direct role in 
controlling the cell cycle. Part of the regulation of the cell cycle is achieved by the 
inactivation and hyper-phosphorylation of negative regulators of the cell cycle such as 
retinoblastoma tumour suppressor (Rb) proteins. Upon gene stress the accumulation of p53 
induces a cell cycle arrest at G1 phase, where DNA can be repaired before replication occurs 
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in the S-phase. The accumulation of p53 up-regulates the expression of p21 proteins. The p21 
protein also known as WAF1 protein inhibits cdks by forming a p21-cdk-cyclin complex 
(Cdk2/A complex). This leads to the accumulation of hypo-phosphorylated Rb proteins. Rb is 
required to regulate the E2F transcriptional factor, however upon hypo-phosphorylation, Rb 
can no longer activate E2F thus resulting in G1 arrest (Figure 2). 
 
Figure 2.  Diagram description of p53 activation and up regulation of genes involved with 
cell cycle arrest (p21) and pro-apoptotic genes (BAX) and the subsequent genes involved in 
inhibiting p53 (MDM2) and anti-apoptotic genes (BCL-2). 
 
b)  The BCL-2 genes and apoptosis 
Members of the Bcl-2 gene family, together with their protein products play an important role 
in apoptosis and are functional mostly with the intrinsic pathway. This Bcl-2 gene was the 
first member to be identified and were called B-cell lymphomas (Gross et al., 1999). The 
protein product of the pro-apoptotic and the anti-apoptotic proteins exert extreme pressure by 
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initially permeating the mitochondrial membrane through either cellular intermembrane 
channels or through cellular pores (Korsmeyer, 1999). TP53 targets Bax to signal apoptosis. 
Bax is translocated into the mitochondria and these results in mitochondrial outer membrane 
permearbilisation, which leads to the subsequent release of cytochrome c into the cytosol, 
thus activating a caspase cascade that will result in apoptosis (Figure 2). Genes such as TP53 
play a functional role in the induction of apoptosis, therefore TP53 and other related genes 
(Bax, p21 and Bcl-2) and their functions will be examined in this study. 
From the process of cell cycle analysis and apoptosis, it is clear that defects in the two 
processes hold the key to a successful cancer drug target. While on the other hand medicinal 
plants and phytochemicals provide an opening to target these two processes. The use of 
traditional medicine is a growing approach for non-surgical treatments in all forms of lung 
cancer. 
1.5. Aim and Objectives 
1.5.1. Aim 
The aim of the project is to identify specific extracts of the South African medicinal plant, 
Lobostemon fruticosus, which display direct anti-cancer activity and cytotoxicity on human 
lung cancer cells. 
1.5.2. Objectives  
 To monitor the changes in cell proliferation of non-small cell lung cancer (A549) cell line 
following treatment with crude plant extract of Lobostemon fruticosus 
 Determine whether these extracts induce apoptosis as a mode of cell death 
 Observe whether these plant extracts affect the apoptotic genes  
 To identify the compounds in Lobostemon fruticosus that might be responsible for cell 
death 
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Chapter Two: Materials and Methods 
2.1. Materials 
A549 non-small lung cancer cell line was purchased at ATCC (USA). The Lobostemon 
fruticosus plant was collected in Hermanus (Western Cape, South Africa).  The A549 cells 
were cultured in small culture flasks containing Dulbecco’s modified eagle media (DMEM 
with L-glutamine, Sigma, USA) which was supplemented with 10%  (v/v) foetal bovine 
serum (FBS, Sigma) and 1% (v/v) penicillin/streptomycin (Sigma). The cells were incubated 
at 37 °C and 5% CO2. Trypsin-EDTA and MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyl-
tetrazolium bromide) were purchased at Sigma- Aldrich (USA).  
2.2. Methods 
2.2.1. Cell culturing 
The A549 cell line was passaged/subcultured regularly (between two and three days) in a 
25 cm
2 
culture flask. Cells were maintained in DMEM/MEM media, supplemented with 10% 
(v/v) foetal bovine serum and 1% (v/v) penicillin/streptomycin. The cells were kept in sterile 
conditions in an incubator maintained at constant 37 °C temperature with 5% CO2.  All the 
cells were allowed to reach 70-80% confluence prior to treatments or harvesting. 
2.2.2. Plant collection and preparation 
Lobostemon fruticosus was collected in the Fernkloof nursery, located in Hermanus in the 
Western Cape (South Africa). Lobostemon fruticosus was air dried at room temperature for 
3 weeks. The whole plant was ground into fine powder. Ten grams of the crude plant was 
dissolved in 100 ml methanol and 100 ml butanol each and allowed to shake at room 
temperature at 150 rpm over night.  The methanol and butanol extracts were then filtered 
using Whatman paper and allowed to dry in the incubator. Final weight of the dried extract, 
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289.6 mg methanol and 96.2 mg butanol, were dissolved in 1 ml DMSO to the final 
concentration of 289.6 mg/ml and 96.2 mg/ml for methanol and butanol, respectively. The 
dissolved extracts were stored in -20 °C.  
2.2.3. MTT-Assay 
Principle 
Measurement of cell viability and proliferation form the basis for numerous in vitro assays of 
a cell population’s response to external factors. The reduction of tetrazolium salts is now 
widely accepted as a reliable way to examine cell proliferation (Mosmann, 1983). MTT (3-(4, 
5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) also referred to as tetrazolium, is 
yellow in colour, this compound is reduced, during cell proliferation, by metabolically active 
cells into formazan which appears purple (Mosmann, 1983). Along with various other 
reactions, the most well notable reason for this occurrence is due, in part, to the active 
dehydrogenase enzymes that produce NADH and NADPH. The crystalline formazan is 
solubilised with DMSO or other detergents and quantified spectrophotometrically (Mosmann, 
1983). 
Technique 
Cells were seeded, at a density of 5000 cells/ 90 μl media each; cell density was determined 
by means of a haemocytometer. The cells were incubated at 37 °C, 5% CO2 overnight to 
allow cells to adhere to the plates and grow. The cells were then treated with two treatment 
controls, camptothecin (CPT) (0.25-5 μM) and (10-200 nM) taxol (TXL); then with methanol 
and butanol extracts at increasing concentrations (1-100 μg/ml). DMSO, methanol and 
butanol were used as controls to the final concentration 0.001% (v/v). The assay had a non-
treatment control, and a blank with only media. The treated cells were incubated for 24 hours 
(h) prior to addition of MTT. A 5 μg/ml MTT stock solution was dissolved in PBS and 
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filtered, 10 μl of the dissolved MTT was added onto each well and incubated for 4 h. Upon 
formation of formazan crystals, 90 μl of DMSO was added in each well to dissolve the purple 
crystals. The plate was read at 570 nm wavelength using the Thermo Scientific™ Multiskan 
Go reader. Cell death was calculated 
                 
                       
                         
        eq. 1 
                                     eq. 2 
The IC50 was determined as 50% cell viability.  
2.2.4. xCELLigence ™ 
Principle 
The xCELLigence ™ system monitors cellular events in real-time, as it measures the 
electrical impedance (resistance) within the interdigitated microelectrodes located below the 
xCELLigence tissue culture plates (Roche xCELLigence™ manual). The use of impedance 
measurements has improved upon the use of conventional endpoint assays in that it provides 
more accurate quantitative assays, not only of the cell count and health but also cellular 
adhesion, viability and morphology (Urcan et al., 2010). The xCELLigence system is used to 
obtain dynamic real time data , to continuously monitors the state of the cells throughout the 
entire experiment, can measure the short-term and long-term cellular changes, and can 
analyse real-time cellular effects as it occurs in its natural environment- this is due to the non-
toxic analysis of the tissue culture (Urcan et al., 2010). 
Technique 
Cells were seeded at 5 × 10
3
 per well and cultured in the chamber of the E-16 plates 
overnight (37 °C, 5% CO2) to allow cells to adhere to the plates and grow. The Cells were 
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then treated with 0.5 μM CPT and 50 nM taxol; then with 35 µg/ml and 45 µg/ml methanolic 
and 50 µg/ml butanolic extracts of L. fruticosus, and control solution of 0.01% (v/v) DMSO, 
methanol and butanol respectively. Cells were then allowed to grow over a period of 72 h. 
2.2.5. DNA fragmentation 
Principle  
Apoptotic cell death can be characterised by observing specific morphological and 
biochemical changes that distinguish it from other forms of cell death, such as necrosis (Nanji 
and Hiller-Sturmhofel, 1997). One of these specific features is DNA fragmentation 
(Basnakian and James, 1994). Cells undergoing apoptosis release endonucleases, enzymes 
that catalyse the hydrolysis of phosphodiester bonds found within a polynucleotide chain. 
DNA is cleaved by the endonuclease enzyme into nucleosomal units (oligomers) that are 
about 180 bp in size (Basnakian and James, 1994). The fragmented DNA is resolved on an 
agarose gel to verify if apoptosis had actually occurred. This method is referred to as DNA 
laddering assay. During apoptosis, the activity of the endonuclease, called caspase-activated 
DNase (CAD), is catalysed by caspase-3, which cleaves the inhibitor of caspase-activated 
DNase (ICAD) (Liu et al., 1997). 
Technique 
Cells that were 70-80% confluent (6 × 10
6
) were treated and incubated for 24 h (CPT and 
TXL) and 48 h (all treatments including DNase control). Detached cells were harvested by 
centrifugation (2054 × g, 5 min, 25 °C). Furthermore, adherent cells were trypsinised for 
2 min, washed with DMEM and harvested by centrifugation (2054 × g, 5 min, 25 °C). gDNA 
was extracted using Quick-gDNA™ miniprep (Zymo Research). The gDNA was run in 1% 
Agarose gel (1× Tris-Borate-EDTA buffer) at 90 V. The agarose gel was then analyzed using 
the Gel-Doc viewer. 
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2.2.6. Flow cytometry: Apoptosis 
Principle 
Flow cytometry is a technique that is used for the analysis of multiple parameters of 
individual cells within heterogeneous populations (Mandy et al., 1995). This method is used 
in various techniques, namely cell counting, immunophenotyping, green fluorescent protein 
(GFP) expression as well as ploidy analysis. When conducing this technique, a large number 
of cells (1000 cells/sec) pass through a laser beam, as these cells pass through the beam a  
light that emerges between the cells is then captured for analysis (Jayat and Ratinaud, 1993). 
This data can be analysed using flow cytometry software (BD Accuri), which can report on 
the cellular characteristics of each of the cells. These characteristics are namely the size, 
phenotype, health and complexity of the cell (Jayat and Ratinaud, 1993).  
Technique 
Cells were treated and incubated for 24 h. Detached cells were harvested by centrifugation 
(2054 × g, 5 min, 25 °C). Furthermore, adherent cells were trypsinised for two min and rinsed 
and harvested by centrifugation (2054 × g, 5 min, 25 °C). Harvested cells were re-suspended 
with 500 μl 1× Annexin V Binding buffer. The cells were then subjected to 5 μl Annexin V-
FITC and 5 μl propidium iodide and incubated for 5 min at room temperature in the dark. 
Cells were then analysed using BD Accuri™ Flow cytometer. 
2.2.7. Cell Cycle analysis 
Principle 
Cell cycle analysis studies the DNA content found in pre-fixed cells by means of flow 
cytometry. The technique aims to identify the stage of DNA development within the pre-
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mitotic phases of the cell cycle. Propidium iodide is the fluorescent stain that is used to bind 
to DNA and indicate the cell cycle phase that DNA population is found.   
Technique 
Cells were allowed to grow to 70%- 80% confluence. This was followed by treatments of the 
cells with 50 nm taxol, 0.5 µM camptothecin, 50 µg/ml of methanol and 50 µg/ml butanol 
extracts for 48 h prior to fixing.  The treated cells were then washed with 1× PBS twice upon 
the removal of media and trypinised for two min with Trypisn-EDTA. DMEM media was 
then added onto trypsinised cells then the cells were harvested by centrifugation (2054 × g, 
3 min, 25 °C). Cells were resusupended in 30 µl of ice cold 1 ×PBS and 70 µl of 100% 
ethanol which was pre-chilled at -20 °C. Cells were kept at -20 °C until they were required 
further experimental procedures. On the day of analysis the fixed cells were stained with 
FxCycle™ PI/RNAse staining solution (Life Technologies) and analyzed by flow cytometry 
and analyzed with the BD accuri™. 
2.2.8. RNA-extraction and reverse transcription  
Principle 
In order to study the specific gene expression of target genes within cells, it is essential that a 
reliable extraction of total non-degraded RNA be conducted (Burgmann et al., 2003). The 
most important aspect of RNA extraction is to prevent RNA degradation. Most protocols 
employ RNase inhibitors such as denaturants, namely sodium-dodecyl sulfate (SDS) or β-
mercaptoethanol, to reduce the loss of RNA or prevent RNA degradation during extraction.  
Technique 
RNA was extracted using NucleoSpin® RNA II extraction kit (Macere-Nagel). 
Contaminating DNA was removed by adding RNase free DNase directly on to the 
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NuclocleoSpin® silica membrane contaminated with DNA. Furthermore, the RNA was 
subjected to repeated washes with two buffers that remove salts, metabolites and any residual 
cellular component. The purified RNA was eluted with RNase-free water and immediately 
stored at -70 °C to ensure RNA stability (NuclocleoSpin® protocol). The RNA integrity was 
confirmed by means of a denaturation gel and the A260/A280 ratio was < 1.7. Extracted 
RNA was reversed transcribed to cDNA using Takara Bio Inc. PrimeScript™ RT reagent Kit 
(Perfect Real Time) using the protocol in Table 1.  
Table 1.  Reverse transcriptase cocktail mixture  
Content Volume (µl) 
5X PrimeScript Buffer  2 
PrimeScript RT 
Enzyme Mix I  
0.5 
Oligo dT Primer  0.5 
Oligo dT Primer  0.5 
dH2O 5.5 
RNA sample 1 
Total 10 
 
The Labnet multigene thermocycler was used with the following conditions: 
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Table 2. Reverse transcription PCR protocol 
 Temperature 
(°C) 
Time (Min) 
1 35 15 
1 85 0.167 
1 Cycle 4 ∞ 
 
2.2.9. Real-Time Polymerase chain reaction (RT-PCR) 
Principle 
Real-time PCR (RT-PCR) uses the same principle of amplification as that of basic PCR. 
However, this method of PCR monitors product formation and amplification in real time. 
This is made possible by the use of the real-time PCR machine which contains specific 
detectors, which detect the fluorescent markers that are stimulated during amplification of 
DNA in each cycle (Bustin et al., 2005).  
Technique 
 Reverse transcribed cDNA was amplified by PCR using the following primers 
a) GADPH:  
Forward – 5′-TGT AGT TGA GGT CAA TGA AGG G- 3′,  
Reverse – 5′-ACA TGC CTC AGA CAC CAT G- 3′;  
b)  p21: 
Forward – 5′ -GAG ACT AAG GCA GAA GAT GTA GAC- 3′, 
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Reverse – 5′ - GCA GAC CAG CAT GAC AGA T- 3′  
c)  P53: 
 Forward – 5′ -GAC GCT AGG ATC TGA CTG C- 3′,  
Reverse – 5′ -GAC ACG CTT CCC TGG ATT G -3′. 
d)  MDM2 
 Forward – 5′-GTG CAT TTC CAA TAG TCA CCT AA- 3′,  
Reverse – 5′-AGA AGG ACA AGA ACT CTC AGA TG- 3′; 
e)  BAX: 
Forward – 5′ –AAA GAT GGT CAC GGT CCA AC- 3′, 
Reverse – 5′ – CAA ACT GGT GCT CAA GGC- 3′  
f) BCL-2:  
Forward – 5′ -AGC CAG GAG AAA TCAAAC AGA G- 3′, 
Reverse – 5′ -GAT GAC TGA GTA CCT GAA CCG -3′.  
 The Luminaris HiGreen™ qPCR  mastermix (Life Science) was prepared  to a final cocktail 
mix of 10 µl (Table 3).  
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Table 3: components of qRT-PCR mix 
Components  Volume (µl) 
2 ×Luminaris HiGreen™ qPCR  
mastermix 
5 
Fwd + Rvs  1 
cDNA 1 
Nuclease free water (make up to 
10 µl) 
3 
Total  10 
 
The Roche light cycler 480 was used to amplify and record PCR amplification: 
Initial denaturation step: 95 °C for 10 min 
Denaturation step: 95°C for 15 sec 
Annealing step: 60 °C for 30 sec        40 Cycles 
Extension step: 72 °C for 30 sec 
Samples data was calculated and analysed using REST 2009 software, a tool developed for 
the analysis of gene expression data from quantitative PCR (qPCR). This is done by 
computing the gene expression ratio from crossing point (CP) values of the target genes 
versus those of the control (GAPDH). Each gene from the different treatments was plotted 
using similar genes from the untreated cells as a reference.  
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2.2.10.  Liquid Chromatography- Mass Spectrometry  
Principle 
Liquid chromatography-mass spectrometry (LC-MS) combines two analytical techniques, 
namely high performance liquid chromatography (HPLC) and mass spectrometry (MS). 
Individually, these techniques are very efficient, however combining the two creates an 
efficient and much more powerful analytical tool  (Korfmacher, 2005). HPLC separates  
compounds found in a mixture by their physical or chemical properties, which include the 
size, charge of specific affinity of that particular compound (Wisniewski, 1992). 
Chromatographic techniques are characterised by the presence of the mobile and stationary 
phase. The stationary phase contains specific compounds (silica or sephadex) that usually 
retard analytes found in the mobile phase. The mobile phase carries the mixture of analytes 
through the stationary phase, where the analytes will then be separated based on their 
chemical or physical properties (Wisniewski, 1992). The analyte will then get separated at 
different times and can then be collected and analysed individually. The length of the 
stationary phase will determine the time and purity of the analyte upon analysis, this means 
that the longer the stationary phase (column) the longer it will take for analytes to separate, 
thus ensuring that the compound in pure. Analytes with similar properties and size can be 
thoroughly distinguished in longer columns. Short columns however, ensure that analytes are 
separated at a faster rate but the purity of the analyte cannot always be ensured, thus, the type 
of column used is determined by the type of chromatographic data that is desired.  
Once the analytes have been separated they enter into the photodiode array (PDA), which 
contains a light source (such as tungsten) which scans compound at different wavelengths 
(Korfmacher, 2005). As the separated compound enters the PDA the light shines through the 
compound and as the compound absorbs the light, there will be a peak at specific wavelength, 
this is due to the fact that each compound has a unique absorbance (Korfmacher, 2005). The 
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point of maximum absorbance (λmax) vs absorbance is part of the PDA display that can be 
used to determine the compound of interest. Another part of the PDA display is absorbance 
versus time, which indicates when the compound was eluted from the column (Korfmacher, 
2005). The information on the PDA displays can give a clear understanding of the compound 
of interest. HPLC can be very effective in determining known compounds in an analyte 
mixture, however, if the analytes have various unknown compounds it could be difficult to 
analyse them. The combination of HPLC with MS does ensure that an unknown compound 
can be identified (Korfmacher, 2005). After PDA analysis, the analyte travels through an 
interface to the MS. When the analyte reaches the MS it immediately interacts with the 
electron spray ioniser (ESI), which vaporises the analyte and subsequently ionises the 
vaporised analyte, with either a negative or positive charge. Upon ionisation the analyte then 
enters the quadrupole, which is made up of four charged rods that keep changing their charge 
rapidly (1000/sec) between negative and positive charges. The charged analytes encounter the 
charged rod and are either deflected or they pass through the quadropole. Deflected analytes 
get lost within the quadrupole chamber and those that pass through the quadrupole hit the 
detector. At the precise moment of impact the detector then record the quadrupole charge. 
The mass of the analyte is determined by the quadrupole charge and the time of impact 
between the compound and the detector. A light compound will have a lower charge recorded 
as opposed to the heavier compound and light compound will travel at a faster speed than a 
much heavier compound (Korfmacher, 2005). Once the analyte is detected, data showing 
various ions and their various intensities will be computed. By combing the data found in MS 
and that of the PDA, unknown compound can then be identified from literature of from 
various MS libraries. 
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Technique  
The samples of both the methanol and butanol extracts were sent to the University of Fort 
Hare for LC-MS. Sample preparation was conducted using the following: 
Table 4. Type  of LC-MS analysis 
 Mass Spectrometer TripleTOF 5600 
 Config Table Version  01 
 Firmware Version  M402001 B4T0301 
M3L2002 B3T0300 
 Component Name  Hybrid Quadrupole-
TOF LC-MS/MS 
Mass Spectrometer 
 Component ID  Triple TOF 5600 
 Manufacturer  AB Sciex Instruments 
 Model  1032150/AD 
 Serial Number  AY22261112 
 Source Housing  DuoSpray Ion Source 
 
Unknown compounds were determined from MS library Mass Bank www.massbank.jp 
2.2.11. Statistical analysis  
The results of each of the experimental procedures, performed either in triplicate or 
duplicates, are the expression of the mean  and standard deviation of the mean. Degrees of 
statistical significance of data sets (duplicate or triplicate) were determined using Student’s t-
test. This was conducted under the inference that p-values ≤ 0.05 were significant. 
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Chapter Three: Results 
3.1.    MTT assay  
The cell viabilty assay was conducted to assess the effects of cell growth of A549 cells that 
were treated with increasing concentrations of the following cytotoxic compounds 
camptothecin (0.25- 15 µM) and taxol (10-500 nM) in comparison to those of the methanol 
and butanol extracts of the medicinal plant Lobostemon fruticosus. A549 cells were treated 
over a 24 hour period and the cytotoxic effects of these treatments were calculated againts the 
untreated  A549 cells. 
The research findings indicated that each of the treatments induced various degrees of cell 
death (cd) at increasing concentrations. Each of the treatments achieved an IC50  at various 
concentrations. Camptothecin-induced 50.5% cd at 1 µM, taxol induced, 50.9% cd at 50 nM.  
The methanol  and butanol extracts of L. fruticosus induced  41.3% cd at 40 µg/ml, and  
49.6% cd at 50 µg/ml , respectively (Figure 3). The negative control DMSO induced 1.4% cd 
at 0.001% (v/v).  The results show that at higher concentrations, cells treated with methanol 
extracts (50 and 100 µg/ml) showed a significant decrease in cell death.  This indicated that 
the extracts of L. fruticosus did reveal levels of cell toxicity at relatively low concentrations 
(Figure 3).  
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Figure 3: Percentage of cell death of treated A549 cells. Cells were treated with increasing 
concentrations of CPT (C 0.25-15 µM), TXL (T 1-500 nM), methanol and butanol extracts of 
L. Fruticosus (M and B 1-100 µg/ml rsp). The control DMSO was prepared a to the final 
concentration of 0.001% (v/v). 
 
3.2. The xCELLigence system 
The xCELLigence system was used to observe cell growth and stability (cell adherence) at 
real time. To achieve this cells were seeded on E-plate 16 to monitor cell impedence and 
viablity in a non-invasive and non-fixative environment. The changes in the cells’ electrical 
impedence were detected and expressed as the cell index.  Seeded cells were allowed to 
attach for 22 h prior to cell treatment (arrow, Figure 4). The assessment of cellular 
proliferation was conducted  using A549 cell line. The growth curve analysis was conducted 
over a period of ± 72 h (3 days) upon cell treatment, at a seeding density of 5000 cells/cm
2
. 
 
The experiment was conducted in duplicates. Negative controls of DMSO (0.001%, v/v), 
methanol and butanol (0.0001%, v/v) were included in order to observe whether the mode of 
cell death was exerted as a result of the treatments or of the the solvents they were extracted 
and dissolved in.  
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Cell index  increased continuously for all treated and untreated cells, however the data shows 
that after a period of 29 h cells treated with CPT  began to show a  decline in cell index,  
indicating that cytotoxicity of CPT  took effect after 29 h of exposure to the cells (Figure 4). 
The results also indicated that the negative controls did not affect cell growth of the A549 
cells. The cells treated with TXL showed a continuous increase in cell growth, however, after 
54 h of treatment, there was a change in the pattern of cell growth, which seems to suggest 
that the cells began responding to the inhibitory effects of TXL. There seemed to be no 
difference in the pattern or degree of cell growth of both the methanol extracts and the 
butanol extract.  
 
Figure 4: Real time analysis of cell growth of treated A549 cells. Cell growth of untreated 
and treated A549 cells was analysed using xCELLigence system. Cells were seeded and 
incubated for 24 h prior to treatment (indicated by the arrow). 
 
3.3. DNA fragmentation  
DNA fragmentation profiles were identified by significant smearing on the 
electrophoretogram. The gDNA of treated cells was examined in relation to the gDNA of the 
untreated cells (Figure 5). The treatments were conducted in 24 h for 0.5 µM CPT (C1), 
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15 nM T and 50 nM TXL (T1 and T2 respectively) prior to DNA extraction, 1 µl of DNase 
(D) was added on to 10 µl of gDNA of untreated cells as a positive control (Figure 5A). Cells 
were also treated for 48 h with 0.5 µM CPT (C2), 50 nM TXL (T3), 40µg/ml methanol (M) 
and 50 µg/ml butanol extracts of L. fruticosus (Figure 5B). These finding indicate that DNA 
fragmentation in both the methanolic and the butanolic plant extracts of L. fruticosus showed 
DNA fragmentation began after two days, this was also indicated with CPT and TXL after 
48 h treatments as compared to the 24 h treatments. Degrees of fragmentation were expressed 
in comparison to those of the positive control. 
 
Figure 5: The electrophoretograms for DNA fragmentation of A549 gDNA (A and B). 
Mw is molecular weight marker (100 bp), U is untreated, C is 0.5 µM camptothecin 
treatment, T1 is 15 nM and T2 is 50 nM taxol, M1 is 35 µM methanol extract, M2 is 45 µM 
methanol extract and 50 µM butanol extract.  A control of  DNase treated gDNA (D) was 
used.  
 
3.4. Flow Cytometry 
Cells that were treated with camptothecin, taxol, and the extracts of L. fruticosus were 
analysed, using a flow cytometer, to measure the degree of apoptotic activity after treatment 
over a 24 hour period.  The scatter graph was set up with four quadrants, namely Q1-LL 
which represented viable cells (Annexin-V and Pi negative), Q1-UL which represents dead 
cells, these were either necrotic cells or a cell death (Pi positive), Q1-UR which represents 
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cells that underwent late apoptosis (Annexin-V and Pi positive) and cells that underwent the 
early stages of apoptosis were represented by the Q1-LR quadrant (Annexin-V positive). The 
data of cell death recorded in the UR and LR quadrants were added together in order to sum 
up the total percentage of apoptotic cells that were observed during the assay. The level of 
apoptosis are as follows: 6% (untreated cells), 7.4% (CPT), 27.8% (TXL), 17.6 % (methanol 
extract) and 21.9% (butanol extract). The data was collected in duplicates (n = 2) and 
standard deviation was calculated from the mean (mean±SD), the varying degrees of 
apoptosis were plotted on a bar graph (Figure 6F). The data was statistically analysed using 
Student’s t-test and high degree of significance was observed.  
The analysis of untreated A549 cells indicated that 87.9% of cells located in the Q1-LL 
quadrant, remained viable; 12.1% of cell death was observed with 6.1% in the UL quadrant, 
4.4% in the UR quadrant and 1.6% were found in the LR quadrant (Figure 6A). Cells that 
were treated with CPT indicated that 63.1% of cells located in the LL quadrant remained 
viable; 36.2% cell death was also observed with 29.5% cells in the UL quadrant, 6.7% in the 
UR quadrant, and 0.7% in the LR quadrant (Figure 6B). In Figure 6B, data indicated that 
72.0% of cells treated with TXL remained viable (LL quadrant); 28.0% cell death was 
recorded with 0.2% in the UL quadrant, 2.4% in the UR quadrant and 25.4% in the LR 
quadrant (Figure 6C). Cells treated with methanol extract of the L. fruticosus plant (Figure 
6D) displayed 71.1% viable cells in the LL quadrant; 28.9% cell death was also observed 
with 12.0% in the UL quadrant, 14.4% in the UR quadrant and 2.5% in the LR quadrant. The 
cells that were treated with butanol extracts of the L. fruticosus plant recorded 63.1% of 
viable cells in the LL quadrant; 36.8% cell death was observed with 15.8% cell in UL 
quadrant, 17.5% cell death in the UR quadrant and 3.5% in the LR quadrant (Figure 6E).  
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Figure 6: Scatter graph of A549 cells depicting stages of viable cells (LL), cell death (UL), 
early (LR) and late (UR) stages of apoptosis (A-E). Statistical representation of apoptotic 
cells after treatment in comparison with untreated cells (F). Plots A-E show results of 
apoptotic studies of untreated cells of A549 together with cells treated with camptothecin, 
taxol, methanol and butanol plant extracts, respectively. *Findings were very significantly 
different (p ≤ 0.01), **Findings were extremely significantly different (p ≤ 0.001). 
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3.5. Cell Cycle analysis 
The changes in cell cycle of A549 cells were monitored using a flow cytometer, propidium 
iodide was the stain used to detect the cells’ DNA ploidy at different stages of the cell cycle. 
The histograms of cell cycle analysis illustrate cell progression and inhibition from G0/G1 to 
the S and G2/M phase of cell cycle (Figure 7). Cells were treated for 48 h, fixed with 70% 
ethanol and stained with a DNA staining chemical; propidium iodide for DNA based cell 
cycle distribution analysis. The untreated cells (A) displays some degree of cell cycle 
progression, however CPT (B) and TXL (C) display an inhibition of cell progression at the S 
phase and the plant extracts display inhibition at G0/G1 followed by subsequent cell death.  
The data was collected in triplicates (n = 3) and standard deviation was calculated from the 
mean (mean ± SD), the changes in cell cycle distribution were plotted on a bar graph (Figure 
7F). The population of cells at each stage of cell cycle were statistically analysed using 
Student’s t-test and high degree of significance was observed. 
The cell cycle distributions of treated cells were compared to those of untreated cells, which 
displayed 88.9% cells at G0/G1; 6.6% cells at S, 1.6% cells at G2/M and 2.9% at sub-G0 
(apoptotic) phase (Figure 7A). Cells that were treated with CPT displayed a distribution of 
60.1% cells at G0/G1, 1.2% cells at S-phase, 0.2% cells at G2/M phase and 38.6% cells at sub-
G0 phase (Figure 7B). Cells treated with TXL displayed a distribution of 4.8% cells at G0/G1 
phase; 0.4% cells at S phase, 0% at G2/M phase and 94.8% at sub-G0 phase (Figure 7C). The 
cells that were exposed to methanol extracts of L. fruticosus resulted in 0.1% cells at G0/G1 
phase; 0% cells at both the S and G2/M phases and 99.9% cells at the sub-G0 phase (Figure 
7D). Cells that were treated with butanol extracts of L. fruticosus resulted in 1.3% cell at the 
G0/G1 phase; 0% for cells at both S and G2/M phases and 98.7% cell at the sub-G0 phase 
(Figure 7E).  
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Figure 7: Histogram profiles of A549 cells depicting stages of cell cycle development and 
degree of cell death (cd) before and after treatments. The untreated cells (A) CPT (B) and 
TXL(C) methanol (D) and butanol (E) extracts of L. fruticosus. The population of cells at 
each stage of cell cycle were statistically analysed (F).*Significantly different (p ≤ 0.05) 
**finding were very significantly different (p ≤ 0.01), ***finding were extremely 
significantly different (p ≤ 0.001). 
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3.6.    Real Time polymerase chain reaction (RT-PCR)  
The relative expression of target genes was obtained using GAPDH as the reference gene. 
The measure of gene expression was normalised with the expression ratio set at 1. This 
means that the mean expression points set below 1 signify down regulation of the target gene, 
those set above 1 signify the up regulation of the target gene and those that are found directly 
at one or significantly close to the ratio signify that no changes in gene expression had 
occurred after treatments. The data is presented in the form of box plots (Figure 8 A-D). The 
1% agarose gel was used to verify these findings (Figure 8E). 
The data receive was extrapolated using the Rest 2009 program to statistically construct the 
expression of the crossing point (CP) values. Results for the treatments were plotted using the 
genes from the untreated cells as a reference (Figure 8 A-D) and statistical data was 
constructed from the tables below. 
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Figure 8: Relative expression of apoptotic genes vs. GAPDH in A549 cells. Cells were 
treated with CPT (A), TXL (B), Methanol (C) and Butanol (D) extracts of L. fruticosus over a 
48 hour period.  Genes from untreated cells were used as a reference and the 
electrophoretogram (E) was conducted to view degree of gene expression. The apoptotic 
genes were expressed from untreated cells (U), CPT treated cells (C), TXL treated cells (T), 
cells treated with methanol (M) and butanol (B) extracts. 
 
The data was extrapolated using the Rest 2009 programme to statistically construct the 
expression of the crossing point (CP) values. Results for the treatments were plotted (Figure 8 
A-D) and statistical data was constructed from tables below (Tables 5-8). Insignificant data 
was depicted with N/S; the p-value was displayed as P(H1), the reaction efficiency was 0.9. 
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The results from the CPT treatment indicated that p53 was down (expression mean of 0.158); 
p21 was up (mean of 6.052) and Mdm2 showed no significant (N/S) changes (mean of 
1.593). Bax was up (mean of 1.943) and Bcl-2 was down (mean of 0.192) (Table 5).  
Table 5: Statistical analysis of box plot of CPT 
Gene Type Expression Std. Error 95% C.I. P(H1) Result 
Gapdh REF 1.000         
P53 TRG 0.158 0.078 - 0.325 0.071 - 0.353 0.000 DOWN 
P21 TRG 6.052 3.956 - 9.881 3.148 - 11.854 0.000 UP 
Mdm2 TRG 1.593 0.707 - 4.136 0.496 - 5.327 1.000  N/S 
Bax TRG 1.943 1.556 - 2.441 1.460 - 2.591 0.000 UP 
Bcl-2 TRG 0.192 0.131 - 0.305 0.100 - 0.374 0.000 DOWN 
 
The results from TXL treatment indicated that after cells treated for 48 h indicated that p53 
was down (expression mean of 0.329); p21 was up (mean of 4.091) and Mdm2 was up (mean 
of 2.987). Bax was up (mean of 1.943) and Bcl-2 displayed no significant (N/S) changes in 
expression (mean of 0.568 ) (Table 6).  
Table 6: Statistical analysis of box plot of TXL 
Gene Type Expression Std. Error 95% C.I. P(H1) Result 
Gapdh REF 1.000         
P53 TRG 0.329 0.162 - 0.672 0.155 - 0.702 0.000 DOWN 
P21 TRG 4.091 2.557 - 6.987 2.034 - 8.382 0.000 UP 
Mdm2 TRG 2.987 1.264 - 7.264 1.092 - 8.241 0.000 UP 
Bax TRG 1.943 1.115 - 3.408 1.046 - 3.617 0.000 UP 
Bcl-2 TRG 0.568 0.220 - 1.616 0.166 - 2.006 0.661  N/S 
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The results from cells treated with Methanol extract of L. fruticosus indicated that p53 was 
down (expression mean of 0.168); p21 was up (mean of 8.001) and Mdm2 displayed no 
significant (N/S) changes in gene expression (mean of 0.764). Bax was down (mean of 0.371) 
and Bcl-2 was down (mean of 0.661) (Table 7).  
 Table 7: Statistical analysis of box plot of methanol extract 
Gene Type Expression Std. Error 95% C.I. P(H1) Result 
Gapdh REF 1.000         
P53 TRG 0.168 0.087 - 0.372 0.062 - 0.477 0.000 DOWN 
P21 TRG 8.001 5.928 - 11.526 4.716 - 13.828 0.000 UP 
Mdm2 TRG 0.764 0.323 - 1.853 0.281 - 2.089 0.834  N/S 
Bax TRG 0.371 0.193 - 0.716 0.181 - 0.760 0.000 DOWN 
Bcl-2 TRG 0.178 0.118 - 0.268 0.117 - 0.270 0.000 DOWN 
 
The results from cells treated with the butanol extract of L. fruticosus indicated that p53 was 
down (mean of 0.308); p21 was up (mean of 4.85) and Mdm2 displayed no significant   
(N/S)changes in expression (mean of 0.88). Bax was up (mean of 1.410) and Bcl-2 was down 
(mean of 0.311) (Table 8).  
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Table 8: Statistical analysis of box plot of butanol extract 
Gene Type Expression Std. Error 95% C.I. P(H1) Result 
Gapdh REF 1.000         
P53 TRG 0.308 0.155 - 0.654 0.123 - 0.785 0.000 DOWN 
P21 TRG 4.850 3.457 - 7.261 2.751 - 8.711 0.000 UP 
Mdm2 TRG 0.880 0.396 - 2.325 0.266 - 3.059 0.830  N/S 
Bax TRG 1.410 1.304 - 1.531 1.233 - 1.613 0.000 UP 
Bcl-2 TRG 0.311 0.211 - 0.490 0.168 - 0.588 0.000 DOWN 
 
3.7. Liquid chromatography- Mass spectrometry (LC-MS) 
3.7.1. Methanol extract of Lobostemon fruticosus 
The experiment utilised an untargeted method of profiling extracts of L. fruticosus, by 
applying the quadropole-time-of-flight liquid chromatography- mass spectrometry tandem 
(Q-TOF LC-MS/MS). This would ensure that a broad spectra of peaks from various 
molecules, each with a unique mass-to-charge ratio (m/z), would be detected from the sample 
(Figure 9) (Zhu et al., 2013). The figures below (Figures 10-16) are profiles of compounds 
identified from LC-MS of the methanol extracts of L. fruticosus. The mass of these 
compounds were identified by determining the charge that the quadrupoles were at upon 
molecular impact and the compound’s retention time (RT). The list of compounds found in 
the methanol extract was then tabulated below (Table 9).  
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Figure 9: Non-targeted LC-MS chromatographic profiles of the methanol extracts of 
Lobostemon fruticosus. 
 
1. 2-Hydroxylamino-4 ,6-dinitrotluene 
2-Hydroxylamino-4 ,6-dinitrotluene (C7H7N3O5)  was  one of the compounds identified in the 
methanol extract of L. fruticosus. The mass spectrum was observed at 10.27 min  (Figure 
10A), with mass-to-charge ratio (m/z)  peaks highlighted at 376.0991 and 377.1027 m/z for 
the protiated compound (M+H
+
) and its isotopic species (M+1) respectively (Figure 10B). 
The compound belongs to the toluene family and its molecular mass is 213.15 Da. 
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Figure10: LC-MS chromatographic profile 2-hydroxylamino-4,6-dinitrotouene. 
Spectrum at 10.27 min with the compound structure (A) displaying highlighted peaks at 
376.0991 and 377.1027 m/z (B). 
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2. 4-Hydroxycoumarin 
4- Hydroxycoumarin (C9H6O3) was another compound identified in the methanol extract of 
L. fruticosus. The sample was similar to that of Figure 10 with a  mass spectrum was found at 
10.27 mins (Figure 11A), with mass-to-charge ratio (m/z)  peaks highlighted at 376.0991 and 
377.1027 m/z for the protiated compound (M+H
+
) and its isotopic species (M+1) respectively 
(Figure 11B). The compound belongs to the coumarin family and its molecular mass is 
162.14 Da. 
 
Figure 11: LC-MS chromatographic profile 4-hydroxycoumarin. Spectrum at 10.27 min 
with the compound structure (A) displaying highlighted peaks at 376.0991 and 377.1027 m/z 
(B). 
A 
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M+H+ 
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3. Sarpagine 
Sarpagine (C19H22N2O2) was identified in the methanol extract of L. fruticosus. The 
compound’s mass spectrum was found at 10.27 min (Figure 12A), with mass-to-charge ratio 
(m/z)  peaks highlighted at 209.0808 and 211.1306 m/z for the protiated compound (M+H
+
) 
and its isotopic species (M+2) respectively (Figure 12B). The compound belongs to a group 
of indole alkaloids of the Alkaloid family and its molecular mass is 310.39 Da. 
 
Figure 12: LC-MS chromatographic profile for Sarpagine. Spectrum at 10.27 min with 
the compound structure (A) displaying highlighted peaks at 209.0808 and 211.1306  m/z (B). 
 
B 
A 
M+H+ 
M+2 
45 
 
4. 7-O-methylvitexin 2"-O-β-rhamnoside  
7-O-methylvitexin 2"-O-β-rhamnoside (C28H32O14) is another compound that was identified 
in the methanol extract of L. fruticosus. The compound has a mass spectrum found at 10.311 
min (Figure 13A), with  peaks highlighted at 221.19 m/z f for the protiated compound 
(M+H
+
) and  222.1912 and 223.1315 for its isotopic species (M+1 and M+2 respectively) 
respectively (Figure 13B). The compound belongs to a group of glycoxyflavones of the 
flavonoid family and its molecular mass is 592.1792 Da. 
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Figure 13: LC-MS chromatographic profiles of 7-O-methelylvitexin 2"-O-β-L-
rhamnoside. Spectrum at 10.31 min with the compound structure (A) displaying highlighted 
peaks at 221.1899, 222.1912 and 223.1315  m/z (B). 
 
5. 7-O-β-D-glucosylapigenin 
7-O-β-D-glucosylapigenin (C21H20O10) was identified in the methanol extract of L. fruticosus. 
The compound has a mass spectrum found at 2.106 min (Figure 14A), with peaks highlighted 
at 221.19 m/z f for the protiated compound (M+H
+
) and  various dysregulated peaks (Figure 
14B). The compound belongs to a group of glycoxyflavones of the flavonoid family and its 
molecular mass is 432.28 Da. 
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Figure 14: LC-MS chromatographic profile of 7-O-β-D-glucosylapigenin. Peak 221.1899 
at 2.11 min Spectrum at 2.11 min with the compound structure (A) displaying highlighted 
peaks at 221.183 m/z (B). 
 
6. Hypoglycin B 
Hypoglycin B (C12H18 N2O5) was identified in the methanol extract of L. fruticosus . The 
compound has a mass spectrum found at 2.95 min (Figure 15A), with  peaks highlighted at 
157.08 m/z f for the protiated compound (M+H
+
) and  158.0,159.0 and 160.08 for its isotopic 
species (M+1, M+2 and M+3 respectively) (Figure 15B). The compound has a molecular 
mass is 270.28 Da. 
B 
A 
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Figure 15: LC-MS chromatographic profile of hypoglycin B.  Peak 157.0823 at 2.95 min 
Spectrum at 2.95 min with the compound structure (A) displaying highlighted peaks at 
157.08, 158.0, 159.0 and 160.08  m/z (B). 
 
7. Ricinoleate 
Ricinoleate (C18H33O3) is another compound that was identified in the methanol extract of L. 
fruticosus. The compound has a mass spectrum found at 10.97 min (Figure 16A), with  peaks 
highlighted at 309.13356 m/z f for the protiated compound (M+H
+
) and  310.235, 311.2201 
and 312.2263 for its isotopic species (M+1,M+2 and M+3 respectively) (Figure 16B). The 
compound belongs to a group of unsaturated fatty acids  its molecular mass is 298.461 Da. 
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Figure 16: LC-MS chromatographic profile of Ricinoleate. Peak 309.13356 at 10.97 
Spectrum at 10.97 min with the compound structure (A) displaying highlighted peaks at 
309.13356 ,310.235, 311.2201 and 312.2263  m/z (B) 
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Table 9.  List of compound found in methanol extracts and their function 
Compound Function Reference 
2-hydroxylamino-
4,6-dinitrotoluene 
Unknown  
4-hydroxycoumarin Anti-tumour  
Anticancer  
(Jung et al., 2004, Stanchev 
et al., 2008) 
Sarpagine Induce apoptosis (Feng et al., 2013) 
7-methylvitexin-2”-
O-β-L-rhamnoside 
Anti-
inflammatory 
(Knogge and Weissenbock, 
1984, Panthong et al., 1994) 
7-O-β-D-
glucosylapigenin 
Anti-
inflammatory 
(Arango et al., 2013, 
Panthong et al., 1994) 
Hypoglycin B N/A  
Ricinoleate Anti-
inflammatory 
(Vieira et al., 2000)  
 
3.7.2. Butanol extract profile of Lobostemon fruticosus  
The figures below (Figures 17-25) are chromatographic profiles of compounds identified 
from LC-MS of the butanol extracts of L. fruticosus The experiment uses similar application 
as those described in Figure 10. The figures below (Figures 18-25) are profiles of compounds 
identified from LC-MS of the butanol extracts of L. fruticosus and were identified by their 
mass/charge ratio (Da) and their relative intensities from the mass spectrometry library, Mass 
Bank the compounds were then tabulated below (Table 10).  
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Figure 17: Non-targeted LC-MS chromatographic profiles of the butanol extracts of 
Lobostemon fruticosus. 
 
1. Justicidin B 
Justicidin (C21H6O6) a compound that was identified in the butanol extract of L. fruticosus 
MassBank. The compound has a mass spectrum found at 2.11 min (Figure 18A), with  peaks 
highlighted at 365.1048 m/z  for the protiated compound (M+H
+
) and  366.1083for its 
isotopic species (M+1) (Figure 18B). The compound belongs to a group of aryl naphthalene 
lignans and its molecular mass is 364.348 Da. 
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Figure 18: LC-MS chromatographic profiles of Justidin B. Spectrum at 211 min with the 
compound structure (A) displaying highlighted peaks at 365.1048 and 366.1083  m/z (B). 
 
2. Tropine 
 Tropine (C8H15NO) is another compound that was identified in the butanol extract of L. 
fruticosus. The compound has a mass spectrum found at 2.14 min (Figure 19A), with  peak 
highlighted at 142.1223 m/z f for the protiated compound (M+H
+
) (Figure 19B). The 
compound belongs to a group of tropane alkaloids and its molecular mass is 141.21 Da. 
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Figure 19: LC-MS chromatographic profiles of Tropine. peak 142.1223 M-1 at 2.14 min 
Spectrum at 2.14 min with the compound structure (A) displaying highlighted peaks at 
142.1223 m/z (B). 
 
3. Unidentified compound 
The compound was isolated from the butanol extract of L. fruticosus. The compound has a 
mass spectrum found at 2.81 min (Figure 20A), with  peaks highlighted at 300.1799 m/z  for 
the protiated compound (M+H
+
) (Figure 20B). The compound was no easily identified by the 
Mass bank library. 
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Figure 20: LC-MS chromatographic profiles unknown compound. Spectrum at 2.81 min 
with the compound structure (A) displaying highlighted peaks at 300.1799  m/z (B). 
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4. Flavocommelin 
Flavocommelin (C28H32O15) was isolated from the butanol extract of L. fruticosus. The 
compound has a mass spectrum found at 2.83 min (Figure 21A), with  peaks highlighted at 
631.3403 m/z f for the protiated compound (M+H
+
) and  632.3446 m/z its isotopic species 
(M+1)  (Figure 21B). The compound belongs to a group of natural flavones of the flavonoid 
family and its molecular mass is 608.544 Da. 
Figure 21: LC-MS chromatographic profiles Flavocommelin. Spectrum at 2.83 min with 
the compound structure (A) displaying highlighted peaks at 63.3403 and 3632.3446  m/z (B). 
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5.  Fisetin 
Fisetin (C15H10O6) was isolated from the butanol extract of L. fruticosus. The compound has a 
mass spectrum found at 3.75 min (Figure 22A), with peaks highlighted at 157.083 m/z for the 
protiated compound (M+H
+
) (Figure 22B). The compound belongs to a group of polyphenol 
flavonoids and its molecular mass is 286.236 Da. 
                          
Figure 22: LC-MS chromatographic Fisetin. Spectrum at 3.75 min with the compound 
structure (A) displaying highlighted peaks at 157.083  m/z (B). 
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6.  Unknown compound 
The compound that was isolated from a butanol extract of L. fruticosus. The compound has a 
mass spectrum found at 8.38 min (Figure 23A), with  peaks highlighted at 407.1564 m/z f for 
the protiated compound (M+H
+
) and  408.1597 for its isotopic species (M+1) (Figure 23B).  
                     
Figure 23: LC-MS chromatographic profiles unknown compound. Spectrum at 8.38 min 
with the compound structure (A) displaying highlighted peaks at 407.1564 and 408.1597  m/z 
(B). 
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7. Unknown 
The unknown compound was isolated from the butanol extract of L. fruticosus. The 
compound has a mass spectrum found at 14.01 min (Figure 24A), with  peaks highlighted at 
387.1791  m/z f for the protiated compound (M+H
+
) and  388.1826 m/z for its isotopic 
species (M+1) (Figure 24B). 
Figure24: LC-MS chromatographic profiles unknown compound. Spectrum at 14.01  
min with the compound structure (A) displaying highlighted peaks at 387.179 and 388.1826  
m/z (B). 
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8. Nodakenin 
Nodakenin (C20H24O9) was isolated from the butanol extract of L. fruticosus. The compound 
has a mass spectrum found at 14.02 min (Figure 25A), with  peaks highlighted at 409.16 m/z  
for the protiated compound (M+H
+
) and  410.16848 for its  isotopic species (M+1) (Figure 
25B). The compound belongs to the coumarin family and its molecular mass is 408.4 Da. 
Figure 25: LC-MS chromatographic profiles nodakenin. Spectrum at 14.02 min with the 
compound structure (A) displaying highlighted peaks at 409.1613 and 410.1648  m/z (B). 
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Table 10. Structure and function of some of the compounds identified in L. Fruticosus 
through LC-MS of butanol extracts 
Compound Function Reference 
Justicidin B Cytotoxic (Vasilev et al., 2006) 
Tropine Unknown  
Unknown 
Unknown  
Flavocommelin 
Anti-
inflammatory 
(Oyama and Kondo, 2004, 
Panthong et al., 1994) 
Fisetin  Anti-oxidant (Sengupta et al., 2004) 
Unknown Unknown  
Unknown Unknown  
Nodekenin Anti-
inflammatory 
(Rim et al., 2012) 
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Chapter Four: Discussion and conclusion 
4.1. Discussion 
The focus of this study is to assess the cytotoxic effects of Lobostemon fruticosus on  NSCLC 
cell line A549 and to elucidate the mode of cell death that the plant extract induces. Taxol 
and camptothecin were used as positive controls to compare the similarity in the method of 
cell death that is observed, either by cell arrest (TXL) (Scatena et al., 1998) or by DNA 
fragmentation (CPT) (Sane and Bertrand, 1998). The degree of cellular viability is measured 
not only by cell growth, but also by metabolic activity of the cell. Tetrazolium binds to 
NADH of healthy metabolic cells and it is reduced to formazan crystals during the assay 
(Wang et al., 2010).  Cancer cells growing at an accelerated rate such as those in A549 are 
expected to result in high amounts of formazan crystals after treatment with tetrazolium salts 
(Wang et al., 2010). The experiment was set up to identify the concentration required to 
produce 50% cell death of cells that were treated with camptothecin, taxol and two aqueous 
extracts of Lobostemon fruticosus. The negative control, DMSO, displayed a low degree of 
cell death (Figure 2), thus confirming that cell death observed during the assay was not as a 
result of the dissolving solvent (DMSO). Camptothecin (CPT)  binds to the topoisomerase I 
of DNA and forms a tight DNA-topoisomerase I-CPT complex, that leads to DNA breakage, 
thus initiating the onset of apoptosis (Hsiang et al., 1985). Taxol stabilises cellular 
microtubules, thus hindering any form of cellular functions that are important to the cell such 
as mitosis, cellular movement, cell cycle and spindle formation in DNA during these 
processes (Scatena et al., 1998). These two compounds were once widely used as effective 
chemotherapeutic drugs (Wall and Wani, 1995). Lobostemon fruticosus is a medicinal plant 
that is used in treating a vast range of ailments from treatments of skin diseases (eczema and 
ring worms) to treating STI (syphilis). The findings suggested that the extracts of L. 
fruticosus did display cytotoxic effects on A549 cells at relatively low concentrations, 
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40 µg/ml and 50 µg/ml for both methanol and butanol extracts, respectively (Figure 3). The 
cells treated with methanol extracts did not result in 50% cell death (cd), but could only 
induce 41.3% cd at 40 µg/ml. These findings seem to suggest that extracting the plant with 
crude methanol was not the most effective mode of extraction as opposed to those found in 
butanol. 
The xCELLigence system is a technique that uses a variety of approaches to monitor cell 
viability without introducing any fixatives or poisons or invasive compounds to monitor 
cellular function. In the experiment the system was used in order to observe degree of cell 
viability at real-time. Cell adhesion and cell growth were indicative of cell viability and the 
data was plotted against a normalised cell index. The findings indicated that only cells treated 
with camptothecin displayed a significant decrease in cell viability marked by the decrease in 
CI. These findings did not corroborate with those of the previously conducted assay (Figure 
3). During this experiment the xCELLigence system proved to be an imperfect system when 
monitoring the effects of L. fruticosus on A549 cell line, as it selectively recorded cells that 
were attached to the E-plates and not those that were detached.  
DNA fragmentation is a spontaneous breaking down of the DNA into smaller pieces that tend 
to accumulate within the cell, this could be cause by external DNA stressors or induces with 
various laboratory techniques. The breaking down of DNA in the cell can often result in 
apoptosis, when no possible method of DNA repair can occur (Liu et al., 1997). Thus DNA 
fragmentation is often used to determine degree of apoptosis in cancer studies. In the 
electrophoretograms (Figure 4), specific degrees of smearing in cells treated with either 
methanol or butanol extract were observed. DNA from CPT and TXL treated cells was 
relatively low which could indicate that smaller strands of DNA were lost during 
electrophoresis. The data seems to suggest that there was DNA fragmentation that was 
observed after 48 hour treatments of the A549 cells. 
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The AnnexinV-FITC assay measures the early onset of apoptosis by binding to exposed 
phosphatidylserine (PS), a phospholipid found in cell membranes. During the initial phases of 
apoptosis PS is translocated to the outer membrane where it can bind to Annexin-V during 
the assay (Bortner et al., 1995). Coupled with propidium iodide (PI), the assay can also 
measure late stages of apoptosis and other forms of cell death (Jayat and Ratinaud, 1993). 
The experiment was conducted to measure cell death of cells that were treated within a 24 
hour period. Data indicate that the degree of apoptosis was extremely significant (p ≤ 0.001) 
in TXL, methanol and butanol extracts of L. fruticosus (Figure 6F). CPT did display a very 
significant degree of apoptosis (p ≤ 0.01) in relation to the untreated cells (Figure 6F). Most 
of the data seem to correlate with that observe with DNA fragmentation (Figure 5) which 
were denoted by smearing of gDNA-an indication of late apoptosis (Bortner et al., 1995, Liu 
et al., 1997, Zhang and Xu, 2000).   
Propidium iodide is a stain used to bind to 4 base nucleotide of DNA thus identifying the 
stage that DNA is at different phases of the cell cycle (Jayat and Ratinaud, 1993). This is 
conducted after membrane has been permeabilised with the added fixative. RNase is coupled 
with the PI dye to ensure that no RNA affects DNA integrity at each phase of the cell cycle. 
The findings indicated a significant degree of cell cycle arrest (p ≤ 0.001) in both 
camptothecin and taxol-treated cells as the cycle was inhibited at G0/G1 stage (Figure 7). 
There was, however, little evidence to suggest the same for L. Fruticosus extracts as most of 
the cells occurred in the sub-G0 phase (Figure 7). This indicates that the extract caused a 
significant degree cell death during the cell cycle analysis.  
This idea is also corroborated by the cell cycle analysis assay which indicated that an amount 
of cells treated with L. fruticosus after 48 h lead to cell death, even before entering the G0/G1 
phase of cell cycle, evident by the apoptotic sub G0/G1 peak. This speaks to the idea that 
treatment with L. fruticosus is both dose and time-dependent. When comparing these finding 
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with CPT and TXL the results indicated that both the extracts of L. fruticosus induce 
apoptosis. 
The findings indicate that the plant does exert induced cell death on A549 cells. The results 
observed from MTT- assay (Figure 3) and xCELLigence (Figure 4) indicate that the 
cytotoxic effects of both the plant extracts are time-dependent as cell death was below 50% 
after 24 hour treatment. Furthermore, the compound activity of the extracts did not take effect 
at the expected time. The research findings also indicated that the extracts induced late stages 
of apoptosis as there was evidence of the DNA degradation and large percent of the cells 
population being in the sub-G0 phase, which is indicative of apoptosis (Delobel and Tesniere, 
2014). The extracts of L. fruticosus indicate that the cytotoxic effect can be compared to that 
of camptothecin as there is indication of DNA degradation and most of the cells that were 
treated with extracts populated at the UR quadrant, which was an indication that those cells 
had undergone late stages of apoptosis.  There is a growing interest in the cytotoxic effects of 
various medicinal plants and their application as chemotherapeutic treatments (Mthembu and 
Motadi, 2014; Assaf et al., 2013). This is due to the fact that plant approaches to cancer 
treatment are less harsh as compared to those found in current chemotherapeutic drugs 
(Chabner and Roberts, 2005). These findings suggest that L. fruticosus can be a very effective 
chemotherapeutic treatment of lung cancer. 
Quantitative real-time polymerase chain reaction (qRT-PCR) monitors gene expression at 
real time. The target genes were expressed and quantified relative to the house keeping gene 
(GAPDH) and target genes from untreated cells. The target genes for this experiment; p53, 
p21, mdm-2, Bax and Bcl-2, were used to monitor the molecular pathway with-which L. 
fruticosus extracts would induce apoptosis in comparison to those of TXL and CPT. Data was 
extrapolated from the CP values that were computed by the Light Cycler 480™ software. The 
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box plots were set against an expression ratio of 1 (Figure 8 A-D). Statistical analysis was 
tabulated for each of the gene expression after various treatments (Tables 5-8).  
The research findings demonstrated that the expression of p53 was significantly down-
regulated (p ≤ 0.0001) in all of the treatments (Figure 8, Tables 5-8). This seemed to suggest 
the apoptotic pathways were induced independent of the tumour suppressor gene (p53) in 
CPT, TXL and the L. fruticosus extracts. Mdm-2, a gene responsible for the ubiquitination of 
p53, was significantly up-regulated (p ≤ 0.0001) in both TXL and the butanol extract of L. 
fruticosus, however, there was no significant changes in CPT and methanol extract of L. 
fruticosus (p = 1 and 0.834, respectively). Mdm2 is commonly up-regulated in various cancer 
cells (Tang et al., 2012; Wade et al., 2013); therefore, the up-regulation of mdm2 may not 
have been induced by any of the treatments. P21 (WAF1/CIP1), displayed a very significant 
up regulation (p ≤ 0.0001) in all of the treatments of A549 cell line. The data (Table 5-8) 
suggested that these treatments initiated a p53 independent up-regulation of p21The findings 
imply that treatment of A549 cells with TXL, CPT and the extracts of L. fruticosus triggered 
cell cycle arrest, independent of p53. The finding also demonstrated a significant up-
regulation of Bax (p ≤ 0.0001) in cells that were treated with CPT, TXL and the butanol 
extract of L. fruticosus and significant down regulation in the expression on Bcl-2 in cells that 
were treated with CPT and both the extracts of L. fruticosus. These finding, therefore, speak 
to the idea that treatment with L. fruticosus extracts, of A549 cells induced an apoptotic 
pathway that was independent of p53.  
Treating A549 cell with extracts of L. fruticosus and with positive controls CPT and TXL, 
resulted in induced Bax and p21 apoptotic pathway.  Interestingly, these two genes have been 
vastly reported to be dependent on p53 induction (Kang and Reynolds, 2009; Michieli et al., 
1994). There have been, however, reports of drug mediated apoptotic pathways that were p53 
independent (Wang et al., 2004; Erdal et al., 2005). These reports corroborate with our 
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findings in that the compounds found in L. fruticosus could have induced a p53 independent 
apoptotic pathway. There have been studies that identified that the induction of p21 
(WAF1/CAP1) pathway can occur in the absence of p53 (Michieli et al., 1994; Jeong et al., 
2010), some of which were compound mediated (Jeong et al., 2010). This verifies our 
findings that, compounds such as those found in the L. fruticosus extracts can induce cell 
cycle arrest that is not mediated by p53. There have been various other molecule induced 
pathways that affect BCL-2 family (Kang and Reynolds, 2009; Abou-Nassar and Brown, 
2010). These compounds inhibit Bcl-2 mRNA, directly thus in turn inducing Bax up-
regulation that is p53-independent (Leone et al., 2003). There have been reports of natural 
compounds that mimic the Bcl-2 homology domain 3 (BH3) (Renault et al., 2014). BH3 is a 
domain found in pro-apoptotic proBH3 proteins of the Bcl-2 family, such as Bax and Bak 
(Suryani et al., 2014; Billard, 2013). The anti-apoptotic members of the Bcl-2 family, such as 
Bcl-2 and Bcl-X, prevent apoptosis by forming heterodimers with pro-apototic Bcl-2 proteins 
(van Delft et al., 2006). This heterodimer formation is achieved by binding the BH3 domain 
with the hydrophobic groove of the anti-apoptotic proteins (Suryani et al., 2014). The BH3 
mimetics inhibit Bcl-2 anti-apoptotic proteins by binding to the protein’s hydrophobic 
groove, thus resulting in a Bax dependent mitochondrial degradation pathway that leads to 
apoptosis (Billard, 2013). The results suggest that L. fruticosus extracts, CPT and TXL could 
have induced apoptosis through this pathway. 
The method of extract identification Q-TOF LC-MS/MS is the most effective form of data 
analysis as it ensures that a wide range of compound identification is achieved. These include 
polar, non-polar, thermoliable and semi-volatile compound identification(Korfmacher, 2005). 
Compound identification was achieved through non-target screening of the extracts of L. 
fruticosus. Compound confidence was determined by mass accuracy, retention time and 
isotope pattern, this is done by matching the results with those found in the ABSciex library. 
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The results found using these methods are located in Appendix A and B for methanol and 
butanol extracts respectively. Retention time (RT) is the amount of time a compound spends 
in the column (Korfmacher, 2005). It is the sum of the time it takes a compound to move 
from the column to detector. A compound’s RT will vary depending on the pressure used- as 
it affects flow rate of the solvent), the nature of the stationary phase (both the solvent and 
particle size), the exact composition of the solvent and the temperature of the column (Vipul 
et al., 2005). Most of the metabolic compounds have similar characteristics and size and 
tended to be identified at similar retention time. Compound confidence in both these extracts 
was satisfactory as displayed in the Appendix A and B.  
Some of the compounds that were extracted from the plant such as hypoglycin b, a compound 
that inhibits the oxidation of acyl-CoA dehydrogenase and leads to a decrease in the 
oxidation of certain fatty acids, have had adverse effects on human health. There have been, 
however, studies that indicate that an addition of fatty acid reduce the effects of hypoglycin 
(Hassall and Reyle, 1955; Bressler et al., 1969). Ricinoleate is a fatty acid that was extracted 
from L. fruticosus; therefore, the presence of ricinoleate may antagonise hypoglycin b and its 
toxic effects. Coumarins such as 4- hydroxycoumarin (in methanol extract) and Nodakenin 
(in butanol extract) are a class of compounds that were first isolated in the 1820s from the 
tonka bean  (Lacy and O'Kennedy, 2004). A  vast majority of these compounds, which are 
found throughout the plant kingdom, have been identified to have anti-cancer proprieties, 
furthermore, these compounds were said to combat not only cancer activity but the effects of 
radiotherapy (Marshall et al., 1990). Interestingly, there has been a study that identified a 
curtain coumarin derivative (RKS262), which inhibited the progression of cell cycle analysis 
and induced a Bax dependent apoptotic pathway (Singh et al., 2011; Lopez-Gonzalez et al., 
2004). These findings show that coumarins (such as, 4- hydroxycoumarin and nodakenin), 
found in both the extracts of the medicinal plant, L. fruticosus (Figure 11 and 25, 
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respectively), could have played a crucial role in the apoptotic cell death of the A549 cell 
line. Flavonoids such as flavocommelin, fistetin, and the glycoxyfalvones, are polyphenolic 
compound that are found in various plants and fruits (Panthong et al., 1994), which are 
known to have cytotoxic effect on cancer cells. Research has found that the various types of 
flavonoids exert a specific level of cytotoxicity on various cell lines (Kuntz et al., 1999). 
Other studies (Billard, 2014; Primikyri et al., 2014) have identified natural flavonoids as BH3 
mimetics, which induce apoptosis. These studies confirm that the presence of certain 
flavonoids found in the plant extract could have brought about the p53-independent apoptotic 
pathway. Other compounds with cytotoxic and antioxidant characteristics are alkaloids such 
as tropine and sarpagines, which can be found in various plant extracts  (Lu et al., 2012). 
Most of the compounds identified in both the extracts of L. fruticosus, have cytotoxic and 
anti-inflammatory effects and findings from various studies have noted that most of the 
compounds isolated from the medicinal plant have cytotoxic effects. 
4.2. Conclusion 
The up-regulation of genes in the absence of p53 suggests that treatments induce apoptosis 
using an alternative apoptotic pathway. The experimental findings described above have 
shown that the natural plant compounds of Lobostemon fruticosus, induces cell death in A549 
cells. The plant extracts induced a p53-independent apoptotic mechanism, which was 
mediated by Bax and p21. In these findings the mode of cell death induced by the plant was 
compared to those of taxol and camptothecin, in order to elucidate how the extracts affected 
A549 cells. The results indicated that there was very little difference in the effects of TXL 
and CPT and therefore, the extracts of L. fruticosus were similar to both controls. The results 
suggest that the compounds extracted from L. fruticosus could exert the same mode of action 
as the BH3 mimetics. Most cancer cells have mutated p53 genes; this could result in 
chemotherapeutic drug resistance toward drugs/compounds that induce a p53 dependent 
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apoptotic pathway. The compounds that induce p53-independent apoptotic pathways would 
be very usefully as target therapeutic drugs in treating cancer cells. For future study it would 
be imperative to study the direct effect of the isolated compounds of L. fruticosus on lung 
cancer cells to observe their cytotoxic activity at a molecular level. Furthermore, it would be 
interesting to study the effects of L. fruticosus extracts on a normal cell line (MRC-5). 
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A. Methanol extract 
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B. Butanol extract 
